fda glp-1 compounding crackdown news october 2025 Intensifies on FDA is short-sighted on compounding

FIGURE 6 In sample no

KPV , thymosin alpha-1, and LL-37 are studied for their effects on immune modulation and inflammation

Citrome L

(PubMed) Hankey GJ

Off-label and alternative research uses discussed in the literature and scientific community include gut lining support (BPC-157), recovery from exercise-induced microtrauma, and investigation of mechanisms related to angiogenesis (new blood vessel formation), collagen organization, and inflammatory signaling

However, its endogenous ligand GLP-1 cannot be employed as an effective imaging agent because of its extremely short half-life (less than 5 min) resulting from rapid metabolic degradation